Feasibility of a bihormonal closed-loop system to control postexercise and postprandial glucose excursions

Journal of Diabetes Science and Technology

Volumn 6, Issue 5, 2012, Pages 1114-1122

  Van Bon, Arianne C ^a   Jonker, Lisanne D ^a   Koebrugge, Rob ^b   Koops, Robin ^b   Hoekstra, Joost B L ^a   DeVries, J Hans ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b Inreda Diabetic BV   (Netherlands)

Author keywords

Closed loop; Exercise; Glucagon; Type 1 diabetes

Indexed keywords

GLUCAGON; GLUCOSE; HEMOGLOBIN A1C; INSULIN; ANTIDIABETIC AGENT;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CARBOHYDRATE DIET; CARBOHYDRATE INTAKE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLOSED LOOP SYSTEM; CONTINUOUS INFUSION; CONTROLLED STUDY; DIABETIC DIET; DRUG DELIVERY SYSTEM; FEASIBILITY STUDY; FEMALE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN INFUSION; INSULIN SENSITIVITY; MALE; MEAL; PILOT STUDY; POSTPRANDIAL STATE; TREADMILL EXERCISE; BLOOD; BLOOD GLUCOSE MONITORING; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; EXERCISE; INSTRUMENTATION; METABOLISM; METHODOLOGY; METRONOMIC DRUG ADMINISTRATION; MIDDLE AGED; PHYSIOLOGY; SUBCUTANEOUS DRUG ADMINISTRATION;

ADMINISTRATION, METRONOMIC; ADULT; AGED; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; DIABETES MELLITUS, TYPE 1; EXERCISE; FEASIBILITY STUDIES; FEMALE; GLUCAGON; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INFUSIONS, SUBCUTANEOUS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; MIDDLE AGED; PILOT PROJECTS; POSTPRANDIAL PERIOD;

EID: 84869089191     PISSN: None     EISSN: 19322968     Source Type: Journal    
DOI: 10.1177/193229681200600516     Document Type: Article

References (11)

1. Kowalski AJ. Can we really close the loop and how soon? Accelerating the availability of an artificial pancreas: a roadmap to better diabetes outcomes. Diabetes Technol Ther. 2009;11 Suppl 1:S113-9.
2. Hovorka R, Allen JM, Elleri D, Chassin LJ, Harris J, Xing D, Kollman C, Hovorka T, Larsen AM, Nodale M, De Palma A, Wilinska ME, Acerini CL, Dunger DB. Manual closed-loop insulin delivery in children and adolescents with type 1 diabetes: a phase 2 randomised crossover trial. Lancet. 2010;375(9716):743-51.
3. Kovatchev B, Cobelli C, Renard E, Anderson S, Breton M, Patek S, Clarke W, Bruttomesso D, Maran A, Costa S, Avogaro A, Dalla Man C, Facchinetti A, Magni L, De Nicolao G, Place J, Farret A. Multinational study of subcutaneous model-predictive closed-loop control in type 1 diabetes mellitus: summary of the results. J Diabetes Sci Technol. 2010;4(6):1374-81.
4. Castle JR, Engle JM, El Youssef J, Massoud RG, Yuen KC, Kagan R, Ward WK. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care. 2010;33(6):1282-7.
5. El-Khatib FH, Russell SJ, Nathan DM, Sutherlin RG, Damiano ER. A bihormonal closed-loop artificial pancreas for type 1 diabetes. Sci Transl Med. 2010;2(27):27ra27.
6. Steil GM, Rebrin K, Darwin C, Hariri F, Saad MF. Feasibility of automating insulin delivery for the treatment of type 1 diabetes. Diabetes. 2006;55(12):3344-50. (Pubitemid 44923591)
7. Weinzimer SA, Steil GM, Swan KL, Dziura J, Kurtz N, Tamborlane WV. Fully automated closed-loop insulin delivery versus semiautomated hybrid control in pediatric patients with type 1 diabetes using an artificial pancreas. Diabetes Care. 2008;31(5):934-9.
8. Van Bon AC, Hermanides J, Koops R, Hoekstra JB, DeVries JH. Postprandial glycemic excursions with the use of a closed-loop platform in subjects with type 1 diabetes: a pilot study. J Diabetes Sci Technol. 2010;4(4):923-8.
9. Klingensmith GJ. Intensive diabetes management. 3rd ed. Alexandria: American Diabetes Association; 2003.
10. Luijf YM, van Bon AC, Hoekstra JB, DeVries JH. Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care. 2010;33(10):2152-5.
11. Graf CJ, Woodworth JR, Seger ME, Holcombe JH, Bowsher RR, Lynch R. Pharmacokinetic and glucodynamic comparisons of recombinant and animal-source glucagon after IV, IM, and SC injection in healthy volunteers. J Pharm Sci. 1999;88(10):991-5. (Pubitemid 29480589)